Home » Stocks » CYTR

CytRx Corporation (CYTR)

Stock Price: $1.70 USD -0.16 (-8.38%)
Updated May 10, 2021 3:55 PM EDT - Market closed
Market Cap 43.41M
Revenue (ttm) n/a
Net Income (ttm) -6.70M
Shares Out 34.65M
EPS (ttm) -0.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $1.70
Previous Close $1.85
Change ($) -0.16
Change (%) -8.38%
Day's Open 1.90
Day's Range 1.60 - 1.90
Day's Volume 230,810
52-Week Range 0.39 - 4.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

1 month ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

Other stocks mentioned: ORPH
6 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

6 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerativ...

7 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted...

7 months ago - Business Wire

About CYTR

CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed cytotoxin agent doxorubicin that binds to circulating albumi... [Read more...]

Industry
Biotechnology
IPO Date
Nov 10, 1986
CEO
Steven Kriegsman
Employees
4
Stock Exchange
OTCMKTS
Ticker Symbol
CYTR
Full Company Profile

Financial Performance

Financial Statements